This is a summary of the European public assessment report (EPAR) for Velmetia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Velmetia
Diabetes News
Tag: EMA
Forxiga
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Forxiga (EMA)
Ozempic (semaglutide)
On 14 December 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Ozempic, intended for the treatment of type 2 diabetes. The applicant for this medicinal product is Novo Nordisk A/S (European Medicines Agency)
Toujeo® Receives Positive Opinion from the European Regulatory Authorities
Sanofi announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL)
Glycosmedia is also available as an App: